Drug Discovery and Development: Xylos Corporation

• Publication date: June 2012
• Report size: 18 pages

This report is a source for data, analysis and actionable intelligence on the Xylos Corporation portfolio of new product development . The report provides detailed analysis on each pipeline product with data on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date. Each pipeline product is profiled to cover data on product description, functio...

This report is a source for data, analysis and actionable intelligence on the Xylos Corporation portfolio of new product development . The report provides detailed analysis on each pipeline product with data on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.

Each pipeline product is profiled to cover data on product description, function, technology, indication, and application. The report is also supplemented with a detailed industry player profile and data on clinical trials, wherever applicable.

Scope of the Research

- Detailed industry player profile with data on business description, key industry player facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
- Detailed coverage on all the new product development, by equipment type, by therapy area, by development stage, and by trial phase.
- Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
- Profile of each pipeline product with additional data on product description, function, technology, indication(s), and application.
- Data on relevant clinical trials and product patent details, wherever applicable.
- Information on clinical trial, wherever applicable, is supplemented with data on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Buy

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
- Design and develop your product development, industry ing and sales strategies.
- Exploit Merger and Acquisition opportunities by identifying industry players with the most innovative pipeline.
- Develop successful market-entry strategies .
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Develop competition strategies by identifying the status and likely launch of your competitors’ new product development through review of the clinical trials, stage and phase of development, etc.
- Which are the next high-value products that your competitor would add in its portfolio? – identify, understand and capitalize.

Drug Discovery And Development Industry in the United States

Data table of Contents
Data table of Contents 2
List of Tables 3
List of Figures 3
Key Facts 4
Xylos Corporation - Major Products and Services 5
Xylos Corporation Pipeline Products by Equipment Type 6
Xylos Corporation Pipeline Products by Development Stage 8
Xylos Corporation Pipeline Products by Therapy Area 10
Dura Replacement Product 12
Product Status 12
Product Description 12
Product Milestone 12
MTA Protective Sheet-Resorbable 12
Product Status 12
Product Description 13
Securian Matrix-Resorbable 13
Product Status 13
Product Description 13
Xylos Corporation - Top Competitors 14
Xylos Corporation - Key Executives 15
Xylos Corporation - Operations and Subsidiaries 16
Head Office 16
Recent Developments 17
November 03, 2010: Xylos Receives US$ 244,479 Grant Under QTDP Program 17
February 16, 2010: Xylos Gets New Notice Of Allowance From The USPTO For Oxidation Of Biosynthesized Cellulose Using Periodate 17
January 25, 2010: Xylos Gets New US Patent To Expand Biocellulose Intellectual Property Portolio 17
Appendix 18
Methodology 18
About GlobalData 18
Contact Us 18
Disclaimer 18


List of Tables

Xylos Corporation, Major development 1
Xylos Corporation Key Pipeline Products by Equipment Type 1
Xylos Corporation Key Pipeline Products by Therapy Area 1
Xylos Corporation Key Pipeline Products by Development Stage 1
Xylos Corporation Key Pipeline Products by Trial Phase 1
Xylos Corporation, Major development 4
Xylos Corporation, Major Products and Services 5
Xylos Corporation Number of Pipeline Products by Equipment Type 6
Xylos Corporation Pipeline Products by Equipment Type 7
Xylos Corporation Number of Pipeline Products by Development Stage 8
Xylos Corporation Pipeline Products by Development Stage 9
Xylos Corporation Number of Pipeline Products by Therapy Area 10
Xylos Corporation Pipeline Products by Therapy Area 11
Dura Replacement Product - Product Status 12
Dura Replacement Product - Product Description 12
Dura Replacement Product - Product Milestone 12
MTA Protective Sheet-Resorbable - Product Status 12
MTA Protective Sheet-Resorbable - Product Description 13
Securian Matrix-Resorbable - Product Status 13
Securian Matrix-Resorbable - Product Description 13
Xylos Corporation, Key Executives 15


List of Figures

Xylos Corporation Key Pipeline Products by Equipment Type 1
Xylos Corporation Pipeline Products by Equipment Type 6
Xylos Corporation Pipeline Products by Development Stage 8
Xylos Corporation Pipeline Products by Therapy Area 10

Companies mentioned MicroDose Therapeutx, Inc.
Corium International, Inc.
Dharma Therapeutics, Inc.
Migami, Inc.
Nanocopoeia, Inc.
NuPathe Inc.
Ratio, Inc.
SensiGen, LLC.
Galil Medical Ltd.

Clinical Trial in United States

United States Phase I Clinical Trials

• $ 250
• Industry data
• January 2013

Yearly, From 2006 To 2010
By Business Monitor International
Source: ClinicalTrials.gov, BMI. N.B. Sourced by date of initial registration.

• Industries : Drug Discovery and Development
• Countries : United States

United States Total Clinical Trials

• $ 250
• Industry data
• January 2013

Yearly, From 2006 To 2010
By Business Monitor International
Source: ClinicalTrials.gov, BMI. N.B. Sourced by date of initial registration.

• Industries : Drug Discovery and Development
• Countries : United States

United States Phase Ii Clinical Trials

• $ 250
• Industry data
• January 2013

Yearly, From 2006 To 2010
By Business Monitor International
Source: ClinicalTrials.gov, BMI. N.B. Sourced by date of initial registration.

• Industries : Drug Discovery and Development
• Countries : United States

United States Phase Iii Clinical Trials

• $ 250
• Industry data
• January 2013

Yearly, From 2006 To 2010
By Business Monitor International
Source: ClinicalTrials.gov, BMI. N.B. Sourced by date of initial registration.

• Industries : Drug Discovery and Development
• Countries : United States

United States Phase Iv Clinical Trials

• $ 250
• Industry data
• January 2013

Yearly, From 2006 To 2010
By Business Monitor International
Source: ClinicalTrials.gov, BMI. N.B. Sourced by date of initial registration.

• Industries : Drug Discovery and Development
• Countries : United States